Skip to main content

Truxima News

Dozens of COVID Virus Mutations Arose in Man With Longest Known Case

FRIDAY, April 19, 2024 – An immune-compromised man with a year-and-a-half-long COVID infection served as a breeding ground for dozens of coronavirus mutations, a new study discovered. Worse, several...

Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products

October 26, 2023 – Over the last eight years, FDA has approved more than 40 biosimilar products (biosimilars), and they have become an important treatment option for health care professionals and...

FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan

July 23, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment...

FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan

November 28, 2018 – The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Non-Hodgkin's Lymphoma

Truxima patient information at Drugs.com